Sancilio and Company, Inc.: Developing Good Science Into Great Medicine

Published Online: Wednesday, August 29, 2012
Follow Pharmacy_Times:

Sancilio and Company, Inc., (SCI) is a vertically integrated biopharmaceutical company founded by Fred Sancilio, PhD, in 2007 and headquartered in Riviera Beach, Florida. We are uniquely positioned in the marketplace, leveraging our long-term relationships for quality products with demand in both the retail and institutional segments.

Sancilio and Company is an emerging generic pharmaceutical company that specializes in the development, manufacture, and sale of cardiovascular, dental, and women’s health products. Product offerings include Ocean Blue® Professional Omega-3 2100™ , which contains 2100 mg of omega-3 per serving, chewable and liquid prescription sodium fluoride supplements for the prevention of cavities in children, and prescription chewable prenatal vitamins for women who are pregnant or may become pregnant. We have a robust product pipeline utilizing a state-of-the-art manufacturing facility, with several products in various stages of development.






Our Florida-based research laboratories are staffed with highly qualified and experienced scientists, and our fully operational cGMP production facilities enable us to manufacture products that are then sold through our domestic and international distribution channels. The SCI team currently consists of approximately 70 employees, including 5 PhDs.

All Sancilio products are manufactured in the United States.

Additional information about SCI can be found at www.sancilio.com and www.oceanblueprofessional.com.

Related Articles
Almost all women and seniors with atrial fibrillation should be receiving blood thinners, advises a new analysis of updated clinical practice guidelines.
Casting doubt on previous conjectures, a new study suggests that statins do not protect patients against Parkinson’s disease.
A new FDA approval has given women seeking long-term birth control an additional option.
Even short-term treatment with nonsteroidal anti-inflammatory drugs is associated with significant increases in bleeding and cardiovascular event risk in patients receiving antithrombotic therapy after a heart attack.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$